Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AliveDx presenta el formulario 510(k) ante la Administración de Fármacos y Alimentos de Estados Unidos (FDA)

      AliveDx Logo

      News provided by

      AliveDx

      Sep 04, 2025, 11:33 ET

      Share this article

      Share this article


      - AliveDx anuncia la presentación del formulario 510(k) ante la Administración de Fármacos y Alimentos de Estados Unidos (FDA) para su ensayo de vasculitis (VAS) MosaiQ AiPlex®

      EYSINS, Suiza, 4 de septiembre de 2025 /PRNewswire/ -- AliveDx, la empresa global de diagnóstico in vitro que busca transformar la atención al paciente, anunció hoy que presentó una notificación previa a la comercialización 510(k) a la Administración de Fármacos y Alimentos de Estados Unidos (FDA) para el ensayo de vasculitis (VAS) MosaiQ AiPlex®*.

      El ensayo multiplex MosaiQ AiPlex® VAS está diseñado para mejorar las pruebas de anti-MPO, anti-PR-3 y anti-GBM para vasculitis asociadas a anticuerpos anticitoplasma de neutrófilos (ANCA) y enfermedad anti-GBM (enfermedad de Goodpasture), y para optimizar la obtención de resultados que apoyen el diagnóstico de vasculitis autoinmune. El ensayo está diseñado para usarse en el instrumento MosaiQ, recientemente aprobado por la FDA, Clase II y exento de la norma 510(k). El ensayo equivalente está disponible comercialmente en países con marca CE de IVDR desde julio de 2025, tras obtener la certificación de IVDR.

      Ensayo multiplex MosaiQ AiPlex® VAS*: Rápido, fácil y completo

      El ensayo multiplex MosaiQ AiPlex VAS está diseñado para detectar simultáneamente tres marcadores de autoanticuerpos (MPO, PR3 y GBM) utilizando solo 10 µl de suero del paciente. El ensayo se ejecuta en el instrumento MosaiQ y proporciona un único informe de resultados que abarca los tres marcadores.

      Estos marcadores se describen en los Criterios de Clasificación ACR/EULAR de 2022 para vasculitis asociadas a ANCA[1]-[3] y en la Guía de Práctica Clínica KDIGO de 2021 para el Manejo de Enfermedades Glomerulares[4].

      "Presentar la notificación previa a la comercialización 510(k) a la FDA para nuestro microensayo MosaiQ AiPlex VAS es un paso importante en el avance de soluciones diagnósticas innovadoras para médicos y pacientes en Estados Unidos", afirmó Manuel O. Méndez, consejero delegado de AliveDx. "A nivel mundial, AliveDx y nuestros socios avanzamos en nuestro objetivo de ofrecer soluciones que aporten mayor valor clínico y económico, con el objetivo final de mejorar los resultados de los pacientes."

      Esta notificación previa a la comercialización se suma a los recientes logros de AliveDx, que ha lanzado más de 90 productos de diagnóstico in vitro (IVD) a nivel mundial en los últimos 12 meses, incluyendo ensayos diseñados para proporcionar información diagnóstica integral para la enfermedad celíaca, las enfermedades del tejido conectivo y la vasculitis. Esta amplia gama proporcionará información crucial que permitirá a los médicos atender las necesidades de los pacientes.

      *Este producto no está disponible actualmente en Estados Unidos, ni ha sido autorizado ni aprobado por la Administración de Fármacos y Alimentos (FDA) de Estados Unidos

      Acerca de la solución MosaiQ®

      MosaiQ es una solución de diagnóstico in vitro (IVD) de vanguardia para enfermedades autoinmunes, alergias y otras enfermedades. La plataforma de microensayos planares multiplexada y totalmente automatizada permite realizar pruebas sindrómicas para afecciones complejas. Esta plataforma intuitiva ofrece un alto rendimiento con acceso aleatorio continuo y proporciona resultados rápidos y precisos que abordan las necesidades y expectativas cambiantes de eficiencia en el laboratorio.

      Acerca de AliveDx

      En AliveDx, nuestra misión es potenciar el conocimiento diagnóstico, transformar la atención al paciente e innovar para la vida. Con más de 30 años de experiencia en diagnóstico in vitro, nos dedicamos a forjar el futuro del diagnóstico global en enfermedades autoinmunes, alergias y otras enfermedades. Nuestras soluciones innovadoras permiten a los laboratorios y profesionales clínicos acelerar el diagnóstico, mejorando la vida de los pacientes y fomentando un entorno de trabajo positivo y sostenible para los profesionales sanitarios. Nuestra cartera incluye las marcas Alba, MosaiQ y LumiQ. Estas soluciones buscan generar valor tanto económico como clínico simplificando los flujos de trabajo del laboratorio y proporcionando resultados rápidos y precisos que optimizan la toma de decisiones clínicas. En AliveDx, innovamos para la vida.  

      Para obtener más información sobre AliveDx y sus soluciones de diagnóstico in vitro (IVD), visite www.alivedx.com y conéctese con nosotros en LinkedIn y X.  

      ©AliveDx Suisse SA. 2025. El logotipo de AliveDx, AliveDx, MosaiQ y MosaiQ AiPlex son marcas comerciales o marcas registradas de las empresas del grupo AliveDx en diversas jurisdicciones. Los menús y las funciones están sujetos a cambios. Es posible que no todos los métodos estén disponibles en todos los territorios.

      1. Robson JC et al. 2022 ACR/EULAR GPA Classification Criteria.Ann Rheum Dis. 2022;81(3):315–320.  
      2. Suppiah R et al. 2022 ACR/EULAR MPA Classification Criteria.Ann Rheum Dis. 2022;81(3):321-326.  
      3. Grayson PC et al. 2022 ACR/EULAR EGPA Classification Criteria.Ann Rheum Dis. 2022;81(3):309-314.  
      4. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.  

      Logo: https://mma.prnewswire.com/media/2657402/5489172/AliveDx_Logo.jpg

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.